Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 3Congenital Abnormalities 2Rectal Neoplasms 1Leukemia 1

Interventions

Cytarabine 30fludarabine phosphate 13Etoposide 12Cyclophosphamide 11Mitoxantrone 10Peripheral Blood Stem Cell Transplantation 9Decitabine 9Tacrolimus 7Filgrastim 7Mycophenolic Acid 6Bortezomib 6Idarubicin 5Flow Cytometry 5Daunorubicin 5Antilymphocyte Serum 5tipifarnib 4sargramostim 4Whole-Body Irradiation 4Vorinostat 4Radiotherapy 4Cyclosporine 4Cord Blood Stem Cell Transplantation 4Clofarabine 4Busulfan 4alvocidib 3Polymerase Chain Reaction 3Melphalan 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tanespimycin 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Congenital Abnormalities × midostaurin × Clear all
NCT00093600 2020-12-19

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Novartis

Phase 1 Completed
69 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01174888 2016-07-06

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
34 enrolled
MyeloidOther hematologic neoplasm

Congenital Abnormalities, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡